By Nadir
Getting a medical device cleared or approved feels like the finish line. For many device teams, it turns out to be the halfway point. A hospital can buy a product only if the budget works, and a physician will use it more often when the procedure is paid for. That means coverage, coding, and payment decide much of a device's commercial future, often more than the clearance letter does.
This article walks through how reimbursement works for devices in the United States and why it should shape decisions long before launch.
The FDA asks whether a device is reasonably safe and effective for its intended use. Payers ask a different question: is this device reasonable and necessary for their members, and does it improve outcomes enough to justify paying for it?
The evidence that satisfies one does not always satisfy the other. A trial built to show substantial equivalence or safety may not tell a payer whether patients actually do better, need fewer follow-up visits, or return to work sooner. Firms that plan their clinical programs with both audiences in mind, such as Health Policy Associates, a Massachusetts consultancy focused on FDA regulatory, clinical, and quality work, tend to stress early that study design choices carry consequences well past the submission.
Payer needs belong in the room when endpoints, comparators, and follow-up periods are chosen, not after the data is locked.
| Piece | What it answers | Common examples |
|---|---|---|
| Coverage | Will the payer pay for this at all, and for which patients? | National and local coverage policies, private payer medical policies |
| Coding | How is the service or product described on a claim? | CPT codes for procedures, HCPCS Level II codes for supplies, ICD-10 codes for diagnoses |
| Payment | How much does the provider receive? | Hospital inpatient groupings, outpatient payment groups, physician fee schedules |
A new device might fit neatly into an existing procedure code, which makes billing easy. But if the payment attached to that code was set for older, cheaper technology, hospitals may lose money each time they use the new product. That gap can quietly slow adoption even when clinicians like the device.
Medicare matters to device companies for two reasons. It covers a large share of patients in many therapeutic areas, and many private insurers watch its policies closely when writing their own.
Medicare coverage can come from a national coverage determination, which applies across the country, or from local coverage determinations written by the regional contractors that process claims. Where no specific policy exists, contractors make claim-by-claim decisions, which can lead to uneven payment across regions.
Several programs exist to help new technology through the early years:
New technology add-on payments can give hospitals extra inpatient payment for qualifying technologies while standard rates catch up.
Transitional pass-through payments serve a similar role in the hospital outpatient setting.
Transitional Coverage for Emerging Technologies is a pathway for certain FDA-designated Breakthrough Devices that aims to speed up national coverage review.
Each program has its own eligibility rules and application cycles. The current details are published on the Centers for Medicare & Medicaid Services website, and they change often enough that teams should check them every planning cycle rather than relying on last year's notes.
Private insurers write their own medical policies. Some follow Medicare closely. Others label new technology as "investigational" until more evidence is published, which can block coverage for years.
Hospitals add another layer. Many route new device requests through a value analysis committee that looks at price, clinical evidence, and impact on length of stay or staffing. A sales team may win over a surgeon and still lose at the committee if the hospital cannot see how the cost fits within the payment it receives.
That is why device companies increasingly prepare a simple economic story alongside the clinical one. A clear budget impact model that a hospital finance team can follow is often more useful than a dense cost-effectiveness paper.
Teams that handle this well tend to follow a few habits:
Map the current pathway early. Identify which codes would likely be used today, what they pay, and in which care settings.
Talk to payers and clinicians before pivotal trials. Ask what outcomes would change their minds. Quality of life, avoided hospital stays, and return to function often matter more to payers than technical performance.
Choose comparators carefully. Payers want to know how the device compares with the current standard of care, not just with nothing.
Plan for longer follow-up. Durable results are often what move a payer from "investigational" to covered.
Budget time for coding changes. A new CPT code can take a long time to be created and valued, and the process runs on a fixed annual calendar.
Track the site of care. Payment can differ a lot between inpatient, outpatient, ambulatory surgery center, and office settings, and that difference can decide where a device is used.
Reimbursement can feel far from the bedside, but it is closer than it looks. The tools available in a hospital, the procedures offered in a clinic, and the time it takes for a promising technology to reach patients all reflect coverage and payment decisions.
Clinicians also play a direct role. Specialty societies help shape coding proposals, contribute to coverage reviews, and publish guidelines that payers cite. Physicians who publish real-world outcomes give payers the evidence they ask for.
A device succeeds commercially when regulators, payers, providers, and patients all see enough value to say yes. Clearance opens the door, but coverage, coding, and payment decide how many patients actually walk through it.
MBTPG/ARC